Join our LinkedIn PATENTSCOPE users Community Group
ご意見送信
設定

設定

出願の表示

検索結果 25,056 件
官庁 all 言語 語幹処理 true 同じパテント ファミリーに属する文献は 1 つにまとめて表示する true 非特許文献 (NPL) を含める false
RSS フィードを生成するには WIPO ユーザ アカウントが必要です

検索式の保存

プライベートに設定された検索式は、ユーザがログインしたときのみ表示可能であり、RSS フィードの購読はできません

検索式のツリー表示

条件の絞込み

官庁
全て
検索する言語を選択してください
語幹処理では、検索用語の語形変化を除いて、語幹のみを対象に解釈します。
例えば、「fishing」、「fished」、「fish」、「fisher」などの単語は、語形変化が除かれ、語幹の「fish」として解釈されます。
したがって、「fisher」という単語の検索結果では、語幹「fish」の語形が変化したさまざまな単語の検索結果も反映されます。
同じパテント ファミリーに属する文献は 1 つにまとめて表示
非特許文献 (NPL) を含める

検索式全体

IC:C12N AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

この画面で利用可能なショートカット キー

一般
検索入力欄に移動
CTRL + SHIFT +
結果一覧に移動
CTRL + SHIFT +
文献詳細に移動
CTRL + SHIFT +
次のページに進む
CTRL +
前のページに戻る
CTRL +
結果一覧での操作 ([結果一覧に移動] 後の操作)
次の文献/図に移動
/
前の文献/図に移動
/
上へスクロール
Page Up
下へスクロール
Page Down
一番上までスクロール
CTRL + Home
一番下までスクロール
CTRL + End
文献詳細での操作 ([文献詳細に移動] 後の操作)
次のタブに移動
前のタブに移動

結果分析

1 / 2,506
1.WO/2014/045254HUMAN BETACORONAVIRUS LINEAGE C AND IDENTIFICATION OF N-TERMINAL DIPEPTIDYL PEPTIDASE AS ITS VIRUS RECEPTOR
WO - 27.03.2014
国際特許分類 (IPC) C12N 7/00
C化学;冶金
12生化学;ビール;酒精;ぶどう酒;酢;微生物学;酵素学;突然変異または遺伝子工学
N微生物または酵素;その組成物;微生物の増殖,保存,維持;突然変異または遺伝子工学;培地
7ウイルス,例.バクテリオファージ;それを含む組成物;その調製または精製
 出願番号 PCT/IB2013/058772 出願人 ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM 発明者 HAAGMANS, Bartholomeus, Leonardus
The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.
2.WO/2022/023734CORONAVIRAL PACKAGING SIGNALS
WO - 03.02.2022
国際特許分類 (IPC) A61K 39/12
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
39抗原または抗体を含有する医薬品製剤
12ウイルス抗原
 出願番号 PCT/GB2021/051934 出願人 UNIVERSITY OF LEEDS 発明者 CLARK, Sam
The present invention relates to virus like particles, vaccines and delivery vectors utilising coronavirus packaging signals, and therapeutic agents targeting such packaging signals.
3.WO/2022/175436INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION
WO - 25.08.2022
国際特許分類 (IPC) A61P 31/14
A生活必需品
61医学または獣医学;衛生学
P化合物または医薬製剤の特殊な治療活性
31抗感染剤,例.抗菌剤,消毒剤,化学療法剤
12抗ウィルス剤
14RNAウィルスに対するもの
 出願番号 PCT/EP2022/054047 出願人 MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. 発明者 KUPKE, Sascha
The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
4.WO/2022/165039ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF
WO - 04.08.2022
国際特許分類 (IPC) C07K 16/10
C化学;冶金
07有機化学
Kペプチド
16免疫グロブリン,例.モノクローナル抗体またはポリクローナル抗体
08ウイルスからの物質に対するもの
10RNAウイルスから
 出願番号 PCT/US2022/014103 出願人 TALEM THERAPEUTICS LLC 発明者 ROODINK, Ilse
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
5.20210246170Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
US - 12.08.2021
国際特許分類 (IPC) C07K 14/005
C化学;冶金
07有機化学
Kペプチド
1421個以上のアミノ酸を含有するペプチド;ガストリン;ソマトスタチン;メラノトロピン;その誘導体
005ウイルスから
 出願番号 17163357 出願人 Janssen Pharmaceuticals, Inc. 発明者 Johannes Petrus Maria Langedijk

The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

6.WO/2023/064538COMPOSITIONS CONTAINING CORONAVIRUS PROTEINS AND EPITOPES
WO - 20.04.2023
国際特許分類 (IPC) A61K 39/215
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
39抗原または抗体を含有する医薬品製剤
12ウイルス抗原
215コロナウィルス科,例.ニワトリ伝染性気管支炎ウィルス
 出願番号 PCT/US2022/046682 出願人 LA JOLLA INSTITUTE FOR IMMUNOLOGY 発明者 SHRESTA, Sujan
The present application relates to compositions of matter, processes and uses of compositions of matter relating to Coronavirus proteins, peptides and epitopes, for example, for therapeutic or preventative vaccination against one or more Coronavirus species, subspecies, or strains, and/or for inducing, enhancing, or sustaining an immune response against at least one Coronavirus serotype or species. The Coronavirus may be, for example, SARS-CoV-2, SARS-COV, MERS-COV, OC43, or any coronavirus, including the betacoronaviruses.
7.WO/2021/207213METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19
WO - 14.10.2021
国際特許分類 (IPC) C07K 16/10
C化学;冶金
07有機化学
Kペプチド
16免疫グロブリン,例.モノクローナル抗体またはポリクローナル抗体
08ウイルスからの物質に対するもの
10RNAウイルスから
 出願番号 PCT/US2021/025980 出願人 UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 発明者 OSTROV, David A.
Methods of preventing or treating infection by a SARS-CoV-related betacoronavirus are described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-related betacoronavirus-related illness a small molecule drug and/or an antibody that binds to the ACE2-SARS interaction domain of either ACE2 or SARS-CoV-2 spike protein. Also described are vaccines comprising S-protein polypeptides corresponding to the ACE-2 interaction domain.
8.3173187METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS
CA - 14.10.2021
国際特許分類 (IPC) A61K 31/195
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
185酸;その無水物,ハロゲン化物または塩,例.硫黄の酸,イミド酸,ヒドラゾン酸,ヒドロキシム酸
19カルボン酸,例.バルプロ酸
195アミノ基を持つもの
 出願番号 3173187 出願人 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 発明者 TRIPP, RALPH A.
Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and/or prophylactic. The amount of probenecid, metabolite or analog thereof, or pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
9.WO/2021/216729CELLULAR VACCINE PLATFORM AND METHODS OF USE
WO - 28.10.2021
国際特許分類 (IPC) A61K 39/02
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
39抗原または抗体を含有する医薬品製剤
02バクテリアの抗原
 出願番号 PCT/US2021/028427 出願人 INTIMA BIOSCIENCE, INC. 発明者 CHOUDHRY, Modassir
Cellular vaccine platforms, such as vaccine immune viral opsonization platforms, for eliciting host immune responses are disclosed. Also disclosed are the methods of making and using the cellular vaccine platforms in stimulating host immune responses.
10.WO/2023/030476IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO - 09.03.2023
国際特許分類 (IPC) C07K 14/165
C化学;冶金
07有機化学
Kペプチド
1421個以上のアミノ酸を含有するペプチド;ガストリン;ソマトスタチン;メラノトロピン;その誘導体
005ウイルスから
08RNAウイルス
165コロナウイルス科,例.ニワトリ伝染性気管支炎ウイルス
 出願番号 PCT/CN2022/116668 出願人 MEDIGEN VACCINE BIOLOGICS CORPORATION 発明者 CHEN, Charles
Provided are immunogenic compositions and methods for immunization against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially an immunogenic composition having a recombinant SARS-CoV-2 S protein derived from Beta (B. 1.351) variant and methods using an immunogenic composition derived from SARS-CoV-2 Beta (B. 1.351) variant.
# -